. Author manuscript; available in PMC: 2023 Feb 1.

Published in final edited form as: Transplant Cell Ther. 2021 Nov 28;28(2):72.e1–72.e8. doi: 10.1016/j.jtct.2021.11.014

Table 6.

Analysis of response to bridging chemotherapy on outcomes.

Outcome	High disease pre-bridge → high disease pre-CAR, n = 15¹	High disease pre-bridge → low disease pre-CAR, n = 8¹	Low disease pre-bridge → low disease pre-CAR, n = 8¹	Low disease pre-bridge → high disease pre-CAR, n = 4¹	p-value²
1 Month Response CR	11 (73%)	6/7^* (86%)	8 (100%)	2/3^* (67%)	0.39
1 Month Response CR MRD Negative	11 (73%)	5/7^* (71%)	8 (100%)	1/3^* (33%)	0.093
Grade 3+ Infection During Bridge	12 (80%)	6 (75%)	5 (63%)	2/3^* (67%)	0.89
Grade 3+ Infection After CAR T Cells	8 (53%)	3 (38%)	1 (13%)	2/3^* (67%)	0.22
Grade 3+ Infection Overall (During Bridging or After CAR)	13 (87%)	6 (75%)	6 (75%)	3/3^* (100%)	0.72
Grade 3+ CRS	4 (27%)	1 (13%)	0 (0%)	2 (50%)	0.16
Grade 3+ NTX/ICANS	3 (20%)	3 (38%)	2 (25%)	0 (0%)	0.69

n (%)

Pearson’s Chi-squared test; Fisher’s exact test

Information not available or not applicable for all patients; denominator specifies number of evaluable patients